Hagop Kantarjian

Hagop Kantarjian

UNVERIFIED PROFILE

Are you Hagop Kantarjian?   Register this Author

Register author
Hagop Kantarjian

Hagop Kantarjian

Publications by authors named "Hagop Kantarjian"

Are you Hagop Kantarjian?   Register this Author

100Publications

1299Reads

-Profile Views

How much of US health care spending provides direct care or benefit to patients?

Cancer 2019 May 29;125(9):1404-1409. Epub 2019 Jan 29.

College of Medicine, University of South Alabama, Mobile, Alabama.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cncr.31865DOI Listing
May 2019

Mitochondrial ClpP-Mediated Proteolysis Induces Selective Cancer Cell Lethality.

Cancer Cell 2019 May 2;35(5):721-737.e9. Epub 2019 May 2.

The University of Texas MD Anderson Cancer Center, Molecular Hematology and Therapy, Department of Leukemia, Houston, TX 77030, USA; The University of Texas MD Anderson Cancer Center; Department of Leukemia, Houston, TX 77030, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ccell.2019.03.014DOI Listing
May 2019

Recent advances in the treatment of acute lymphoblastic leukemia.

Leuk Lymphoma 2019 May 16:1-16. Epub 2019 May 16.

b Department of Leukemia , The University of Texas MD Anderson Cancer Center , Houston , TX , USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/10428194.2019.1605071DOI Listing
May 2019

Recent Advances in Adult Acute Lymphoblastic Leukemia.

Curr Hematol Malig Rep 2019 Apr;14(2):106-118

Department of Leukemia, University of Texas, MD Anderson Cancer Center, 1515 Holcombe Boulevard, Box 428, Houston, TX, 77030, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11899-019-00503-1DOI Listing
April 2019

Tagraxofusp in Blastic Plasmacytoid Dendritic-Cell Neoplasm.

N Engl J Med 2019 04;380(17):1628-1637

From the University of Texas M.D. Anderson Cancer Center, Houston (N.P., M.D., H.M.K., M.K.); Dana-Farber Cancer Institute (A.A.L.) and Boston University School of Medicine (J.M.S.), Boston, and Veristat, Southborough (J.B.) - all in Massachusetts; H. Lee Moffitt Cancer Center, Tampa, FL (K.L.S., J.E.L.); City of Hope National Medical Center, Duarte, CA (A.S.S.); Ohio State University, Columbus (S.V.); Winship Cancer Institute of Emory University, Atlanta (W.B.); Duke University Medical Center, Durham, NC (D.A.R.); and Roswell Park Comprehensive Cancer Center, Buffalo (E.S.W.), and Stemline Therapeutics, New York (S. Spence, S. Shemesh, C.L.B., I.B.) - both in New York.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1815105DOI Listing
April 2019

Treatment of relapsed/refractory acute lymphoblastic leukemia.

Clin Adv Hematol Oncol 2019 Mar;17(3):166-175

University of Texas MD Anderson Cancer Center, Houston, Texas.

View Article

Download full-text PDF

Source
March 2019

Characteristics of patients with myeloproliferative neoplasms with lymphoma, with or without JAK inhibitor therapy.

Blood 2019 Feb 22. Epub 2019 Feb 22.

Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, United States.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood-2019-01-897637DOI Listing
February 2019

Emerging treatment paradigms with FLT3 inhibitors in acute myeloid leukemia.

Ther Adv Hematol 2019 15;10:2040620719827310. Epub 2019 Feb 15.

Department of Leukemia, Unit 428, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/2040620719827310DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6378516PMC
February 2019

Myeloid cell leukemia-1 dependence in acute myeloid leukemia: a novel approach to patient therapy.

Oncotarget 2019 Feb 8;10(12):1250-1265. Epub 2019 Feb 8.

The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.18632/oncotarget.26579DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6383813PMC
February 2019

The "American (cancer) patients first" plan to reduce drug prices-A critical assessment.

Am J Hematol 2018 Dec 9;93(12):1444-1450. Epub 2018 Oct 9.

James A. Baker III Institute Chair in Health Economics and Director, Center for Health and Biosciences, Rice University, Houston, Texas.

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1002/ajh.25284
Publisher Site
http://dx.doi.org/10.1002/ajh.25284DOI Listing
December 2018

Prognostic significance of hyperdiploidy in adult acute myeloid leukemia.

Am J Hematol 2018 Nov 9;93(11):E357-E360. Epub 2018 Sep 9.

Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ajh.25240DOI Listing
November 2018

Reply to Starting with a lower daily dose of dasatinib in patients with chronic myeloid leukemia in chronic phase: Less is more, or is it?

Cancer 2018 Nov 1;124(21):4261. Epub 2018 Oct 1.

Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas.

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1002/cncr.31683
Publisher Site
http://dx.doi.org/10.1002/cncr.31683DOI Listing
November 2018

Toward the potential cure of leukemias in the next decade.

Cancer 2018 Nov 6;124(22):4301-4313. Epub 2018 Oct 6.

Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas.

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1002/cncr.31669
Publisher Site
http://dx.doi.org/10.1002/cncr.31669DOI Listing
November 2018

The opioid epidemic in the United States-Overview, origins, and potential solutions.

Cancer 2018 Nov 9;124(22):4279-4286. Epub 2018 Oct 9.

Leukemia Department, The University of Texas MD Anderson Cancer Center, Houston, Texas.

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1002/cncr.31713
Publisher Site
http://dx.doi.org/10.1002/cncr.31713DOI Listing
November 2018

Progress and Innovations in the Management of Adult Acute Lymphoblastic Leukemia.

JAMA Oncol 2018 Oct;4(10):1413-1420

Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1001/jamaoncol.2018.1915DOI Listing
October 2018

A Pilot Trial of Lirilumab With or Without Azacitidine for Patients With Myelodysplastic Syndrome.

Clin Lymphoma Myeloma Leuk 2018 Oct 15;18(10):658-663.e2. Epub 2018 Jun 15.

Department of Leukemia, The University of Texas M.D. Anderson Cancer Center, Houston, TX. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clml.2018.06.011DOI Listing
October 2018

Molecular remission as a therapeutic objective in acute promyelocytic leukemia.

Leukemia 2018 08 19;32(8):1671-1678. Epub 2018 Jul 19.

Department of Biomedicine and Prevention, University Tor Vergata, Rome, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41375-018-0219-5DOI Listing
August 2018

SOHO State of the Art Update and Next Questions: Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia.

Clin Lymphoma Myeloma Leuk 2018 07 22;18(7):439-446. Epub 2018 May 22.

Department of Leukemia, University of Texas M.D. Anderson Cancer Center, Houston, TX. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clml.2018.05.015DOI Listing
July 2018

Clearance of Somatic Mutations at Remission and the Risk of Relapse in Acute Myeloid Leukemia.

J Clin Oncol 2018 Jun 27;36(18):1788-1797. Epub 2018 Apr 27.

Kiyomi Morita, Hagop M. Kantarjian, Feng Wang, Yuanqing Yan, Carlos Bueso-Ramos, Koji Sasaki, Ghayas C. Issa, Sa Wang, Jeffrey Jorgensen, Xingzhi Song, Jianhua Zhang, Samantha Tippen, Rebecca Thornton, Marcus Coyle, Latasha Little, Curtis Gumbs, Naveen Pemmaraju, Naval Daver, Courtney D. DiNardo, Marina Konopleva, Michael Andreeff, Farhad Ravandi, Jorge E. Cortes, Tapan Kadia, Elias Jabbour, Guillermo Garcia-Manero, Keyur P. Patel, P. Andrew Futreal, and Koichi Takahash, The University of Texas MD Anderson Cancer Center, Houston, TX; Kiyomi Morita, The University of Tokyo, Tokyo; and Koichi Takahashi, Kyoto University, Kyoto, Japan.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2017.77.6757DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6008108PMC
June 2018

Durable Remissions with Ivosidenib in IDH1-Mutated Relapsed or Refractory AML.

N Engl J Med 2018 Jun 2;378(25):2386-2398. Epub 2018 Jun 2.

From the University of Texas M.D. Anderson Cancer Center, Houston (C.D.D., H.M.K.); Memorial Sloan Kettering Cancer Center (E.M.S., M.S.T.) and Weill Cornell Medical College (G.J.R.), New York; Institut Gustave Roussy, Villejuif (S.B., C.W.), and Centre Hospitalier Universitaire Bordeaux, Bordeaux (A.P.) - both in France; Northwestern University, Chicago (J.K.A.); Ohio State University Wexner Medical Center, Columbus (A.S.M.); Sylvester Comprehensive Cancer Center, University of Miami, Miami (R.S.); University of Texas Southwestern Medical Center, Dallas (R.H.C.); University of California San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco (G.N.M.), and City of Hope Medical Center, Duarte (A.S.S.) - both in California; University of Colorado School of Medicine, Aurora (D.A.P.); Sarah Cannon Research Institute, Nashville (W.D.); Massachusetts General Hospital Cancer Center (A.T.F.) and Dana-Farber Cancer Institute (R.M.S.), Boston, and Agios Pharmaceuticals, Cambridge (S.C., H.W., V.Z., K.E.Y., S.M.K., H.Y., D.D., B.F., M.G., H.L., S.A., B.W., E.C.A.) - all in Massachusetts; University of Alabama at Birmingham, Birmingham (H.P.E.); Johns Hopkins University, Baltimore (G.T.P.); Washington University School of Medicine, St. Louis (G.L.U.); Mayo Clinic, Jacksonville, FL (J.M.F.); Oregon Health and Science University Knight Cancer Institute, Portland (E.T.); Hollings Cancer Center, Medical University of South Carolina, Charleston (R.K.S.); Winship Cancer Institute of Emory University, Atlanta (M.L.A.); Mayo Clinic, Phoenix, AZ (J.L.S.); and Cleveland Clinic, Cleveland (M.A.S.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1716984DOI Listing
June 2018

Incorporating Immunotherapy Into the Treatment Strategies of B-Cell Adult Acute Lymphoblastic Leukemia: The Role of Blinatumomab and Inotuzumab Ozogamicin.

Am Soc Clin Oncol Educ Book 2018 May;38:574-578

From the Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX.

View Article

Download full-text PDF

Source
http://ascopubs.org/doi/10.1200/EDBK_199505
Publisher Site
http://dx.doi.org/10.1200/EDBK_199505DOI Listing
May 2018

Philadelphia chromosome-positive acute lymphoblastic leukemia in adults: current treatments and future perspectives.

Clin Adv Hematol Oncol 2018 Mar;16(3):216-223

MD Anderson Cancer Center, Houston, Texas.

View Article

Download full-text PDF

Source
March 2018